GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Rhino Biotech Ltd (OTCPK:RBRXF) » Definitions » PE Ratio

Rhino Biotech (Rhino Biotech) PE Ratio : At Loss (As of Jun. 15, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Rhino Biotech PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-06-15), Rhino Biotech's share price is $0.0001. Rhino Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was $-0.00. Therefore, Rhino Biotech's PE Ratio for today is At Loss.

Rhino Biotech's EPS (Diluted) for the six months ended in Dec. 2020 was $-0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was $-0.00.

As of today (2024-06-15), Rhino Biotech's share price is $0.0001. Rhino Biotech's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2020 was $-0.00. Therefore, Rhino Biotech's PE Ratio without NRI ratio for today is At Loss.

Rhino Biotech's EPS without NRI for the six months ended in Dec. 2020 was $-0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2020 was $-0.00.

Rhino Biotech's EPS (Basic) for the six months ended in Dec. 2020 was $-0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2020 was $-0.00.

Back to Basics: PE Ratio


Rhino Biotech PE Ratio Historical Data

The historical data trend for Rhino Biotech's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhino Biotech PE Ratio Chart

Rhino Biotech Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A At Loss N/A At Loss At Loss

Rhino Biotech Semi-Annual Data
Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A At Loss N/A N/A At Loss

Competitive Comparison of Rhino Biotech's PE Ratio

For the Shell Companies subindustry, Rhino Biotech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhino Biotech's PE Ratio Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Rhino Biotech's PE Ratio distribution charts can be found below:

* The bar in red indicates where Rhino Biotech's PE Ratio falls into.



Rhino Biotech PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Rhino Biotech's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=0.0001/-0.001
=-0.1(At Loss)

Rhino Biotech's Share Price of today is $0.0001.
For company reported annually, GuruFocus uses latest annual data as the TTM data. Rhino Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was $-0.00.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Rhino Biotech  (OTCPK:RBRXF) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Rhino Biotech PE Ratio Related Terms

Thank you for viewing the detailed overview of Rhino Biotech's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhino Biotech (Rhino Biotech) Business Description

Traded in Other Exchanges
N/A
Address
294 Heywood House, British West Indies, Anguilla, AIA
Rhino Biotech Ltd formerly Eurasia Energy Ltd is a shell company.
Executives
Nicholas W Baxter 10 percent owner 220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU
Graham Crabtree officer: Chief Financial Officer 294 HEYWOOD HOUSE SOUTH HILL 1A AI-2640
Roger Thomas director 22 HENDERSON ROAD LONDON X0 SW18 3RR
Velda King director, officer: President, C.E.O. SUITE C102 10000 NORTH 31ST AVENUE PHOENIX AZ 85051
Gerald R Tuskey director, officer: C.F.O., Secretary/Treasurer 570 GRANVILLE STREET SUITE 400 VANCOUVER BC A1 V6C 3P1

Rhino Biotech (Rhino Biotech) Headlines

From GuruFocus

Rhino Biotech to Present at the Planet Microcap Showcase

By ACCESSWIRE ACCESSWIRE 05-04-2022